This article is more than 5 years old. Information may no longer be current.
Alcon obtains US rights for Durezol and global rights for Zyclorin from Sirion
Click Here to Manage Email Alerts
HUENENBERG, Switzerland — Alcon has secured regulatory approval and U.S. rights for Durezol and secured global rights, except in Latin America, for Zyclorin, the company announced in a press release.
Rights to both ophthalmic agents are being acquired from Sirion Therapeutics.
Durezol (difluprednate ophthalmic emulsion 0.05%), which was approved by the U.S. Food and Drug Administration in 2008, is a topical ophthalmic corticosteroid indicated for postoperative inflammation and pain from ocular surgery, according to the release.
Zyclorin (cyclosporine), currently undergoing clinical investigation for dry eye and other ocular surface diseases, is a topical ophthalmic immunomodulator and immunosuppressive agent. It is not approved by the FDA.
Alcon will now take on all marketing, promotion and sales of Durezol.
"This acquisition reinforces our ability to drive growth in the near-term with the acquisition of Durezol and add products to our long-term research pipeline with Zyclorin," Stuart Raetzman, Alcon vice president for global marketing and area president for the United States, said in the release. "Durezol's unique capability to effectively and quickly treat both inflammation and pain following ocular surgery makes it a great fit for Alcon's leading product portfolio."
Follow OSNSuperSite.com
on Twitter.